Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.43 |
| ▸ | TNKS | O95271 | 5/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 5/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.40 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649328 | 0.98 | PARP1 (0.44) | PARP1TNKSTNKS2PARP3WNT3A | |
| SCHEMBL6647363 | 0.91 | PARP1 (0.42) | PARP1TNKSTNKS2PARP3WNT3A | |
| SCHEMBL6651964 | 0.91 | PARP1 (0.42) | PARP1TNKSTNKS2PARP3WNT3A | |
| SCHEMBL6647352 | 0.89 | TNKS2 (0.47) | PARP1TNKSTNKS2PARP3WNT3A | |
| SCHEMBL6651974 | 0.88 | TNKS (0.39) | PARP1TNKSTNKS2PARP3WNT3A | |
| SCHEMBL6648890 | 0.85 | PARP1 (0.56) | PARP1TNKSTNKS2HTR2C | |
| SCHEMBL6646707 | 0.85 | PARP1 (0.58) | PARP1TNKSTNKS2HTR2C | |
| SCHEMBL6651055 | 0.82 | PARP1 (0.45) | PARP1TNKSTNKS2HTR2C | |
| SCHEMBL6650044 | 0.80 | PARP1 (0.51) | PARP1 | |
| Hydrochloric Acid SCHEMBL7018458 | 0.77 | PARP1 (0.55) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1469854-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003063874-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | PARP1 1/4885TNKS 57/4885TNKS2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.